Conor Killmurray | Authors


Patients with Cisplatin-ineligible mUC and High PD-L1 Expression Experience Clinical Benefit With Atezolizumab

February 12, 2021

Using the single-agent atezolizumab (Tecentriq) plus chemotherapy versus chemotherapy alone to treat patients in the front-line setting with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma (mUC) revealed additional clinical evidence.

Targeted Intervention Necessary for Low Health-Related Quality of Life Scores in Young Survivors of Colorectal Cancer

January 16, 2021

Data presented at the 2021 ASCO Gastrointestinal Cancers Symposium found that health-related quality of life among younger survivors of colorectal cancer is poor and social and functional well-being are also suffering as treatment durations increase.

Off-the-Shelf CAR T-Cell Therapy Shows Promise in Relapsed/Refractory B-Cell Lymphomas

May 30, 2020

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial.

Algorithm Matches Pediatric Patients with Cancer to Precision Medicines

May 29, 2020

Utilizing data from the INFORM registry, researchers were able to identify high level priority targets in pediatric patients with cancer utilizing an algorithm that matched them to targeted treatments extending their progression-free survival time and showing the feasibility of this program in a real-world setting.